← Leaderboards
Edouard John Trabulsi
Thomas Jefferson University
$2,221,350
Attributed
$4,858,177
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,858,177 · 2
By mechanism
R01$4,858,177 · 2
Top collaborators
- Mathew L Thakur5 shared
- John Eisenbrey3 shared
- Kirk Dennis Wallace2 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- John Eisenbrey$7,634,263
- Colette Shaw$1,596,337
- Kevin Anton$637,912
- Kirk Dennis Wallace$415,477
- Wei Jiang$1,029,626
Others in their field
Other Emerging Leaders on “Design”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- John E West · University Of Texas At Austin$113,883,001
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Kevin Urdahl · Seattle Children'S Hospital$72,239,698
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
Research focus
DesignMalignant NeoplasmsPredictive ValueProteinsBlindedImagePathologySpecificityDiagnosisUltrasoundDiagnosticBiological MarkersBiopsyCancer EtiologyBiochemistryDiagnostic BiomarkerAdvocateCancer CellCancer BiomarkersBenignBenign Prostatic HypertrophyCancer DiagnosisAttentionBreast
Grant awards (8)
Multi-modality detection of RCC Recurrence Post Ablation$589,728
R01 · FY2025 · CA
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer$564,183
R01 · FY2024 · CA
Multi-modality detection of RCC Recurrence Post Ablation$555,321
R01 · FY2024 · CA
Multi-modality detection of RCC Recurrence Post Ablation$691,111
R01 · FY2023 · CA
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer$582,001
R01 · FY2023 · CA
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer$582,001
R01 · FY2022 · CA
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer$593,229
R01 · FY2021 · CA
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer$700,603
R01 · FY2020 · CA